Q4 2025 Day One Biopharmaceuticals Inc Earnings Call Transcript
Key Points
- Day One Biopharmaceuticals Inc (DAWN) reported a significant increase in net product revenue, reaching $155.4 million in 2025, up 172% year over year.
- The company achieved double-digit sequential quarterly growth throughout 2025, with over 4,600 total prescriptions, marking an 180% increase compared to 2024.
- Day One Biopharmaceuticals Inc (DAWN) maintained a strong financial position, ending 2025 with over $440 million in cash and no debt.
- The company is advancing its pipeline with promising programs like the antibody drug conjugate EIL for adenoid cystic carcinoma, which shows early evidence of activity.
- Day One Biopharmaceuticals Inc (DAWN) has favorable payer dynamics, with coverage rates for PLGG above 95% and more than 90% of patients approved on the first request.
- The company faces challenges in expanding awareness of its 3-year Firefly 1 data beyond the KOL community, as it cannot actively promote the data until a peer-reviewed publication is available.
- Despite strong growth, the company acknowledges the need to improve persistence on therapy, identifying opportunities to enhance patient support programs and dose adjustment education.
- The company is still early in the development of its day 301 program, with no specific parameters defined for the upcoming data update.
- Day One Biopharmaceuticals Inc (DAWN) is reliant on the success of its ongoing trials, such as Firefly 2, to establish Ogenda as the standard of care in the frontline setting.
- The company anticipates potential challenges in achieving its 2026 revenue guidance, which depends on continued persistence on therapy and the pace of new patient starts.
Hello ladies and gentlemen, and welcome to the day one biopharmaceuticals 4th quarter and full year 2025 financial and operating results conference call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Please be advised that this conference call is being recorded. I would now like to turn the call over to Joey Peroni, senior Vice President of finance and investor relations. Please go ahead.
Thank you. Hello.
Everyone, and good afternoon. Welcome to day one's 4th quarter in full year 2025 financial and operating results conference call. Earlier today, we issued a press release that outlines the topics we plan to discuss today. You can access the press release and the slides to accompany this conference call in the investors and media section of our website at www.dayonebio.com. An audio webcast with the corresponding
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
